Sepsis does not cause cancer the way tobacco smoke or radiation does, but surviving a serious sepsis episode is linked to a measurably higher rate of cancer diagnosis in the years that follow. A large registry study of more than 18,000 one-year sepsis survivors found cancer incidence ratios of about 1.3 for men and 1.7 for women compared to the general population, meaning sepsis survivors were diagnosed with new cancers at meaningfully higher rates than expected. The relationship is more tangled than simple cause and effect, though, involving immune damage, molecular changes, shared vulnerabilities, and even the treatments given in the ICU.
What the Numbers Actually Show
Two large studies frame the epidemiological picture. A Danish registry study followed 18,550 adults who survived at least one year after a sepsis hospitalization. Over a median follow-up of about three and a half years, roughly 8.8 percent were diagnosed with a new cancer. When compared to expected cancer rates in the broader population, sepsis survivors had a cancer incidence ratio of 1.31 for men and 1.74 for women, and these elevated rates held up across multiple sensitivity analyses designed to rule out obvious confounders.1PubMed Central. Risk of malignant disease in 1-year sepsis survivors, a registry-based nationwide follow-up study
A separate U.S. study using Medicare data in elderly adults found a more nuanced pattern. After correcting for multiple comparisons, sepsis was associated with higher odds of cancers of the colon, rectum, liver, lung, and cervix, along with several blood cancers including acute myeloid leukemia and chronic myeloid leukemia. Some of these associations persisted even when researchers looked specifically at cancers diagnosed more than five years after the sepsis episode, which argues against simple detection bias (the idea that cancer was already growing undetected when the sepsis occurred).2PubMed Central. Sepsis and Risk of Cancer Among Elderly Adults in the United States
Not All Cancers Move in the Same Direction
One of the more puzzling findings is that sepsis does not raise the risk of every cancer equally. The U.S. Medicare study found that while liver, lung, colon, and cervical cancers, as well as certain leukemias, were more common after sepsis, other cancers were actually less common. Breast cancer, prostate cancer, kidney cancer, thyroid cancer, melanoma, and some lymphomas all showed lower odds in sepsis survivors.2PubMed Central. Sepsis and Risk of Cancer Among Elderly Adults in the United States
Why would sepsis be associated with more of one cancer and less of another? Part of the answer may involve detection patterns. Sepsis survivors who are sicker and frailer might be less likely to undergo routine screening for breast or prostate cancer, so those diagnoses could simply be missed or delayed. Another possibility is biological. The immune changes caused by sepsis do not suppress every arm of the immune system equally, and different cancers rely on different immune escape mechanisms. A cancer that depends on evading a specific type of immune cell might thrive when that cell is impaired, while a cancer that depends on a different pathway might not benefit from the same immune disruption. Researchers have not fully sorted out which explanation carries more weight, but the uneven pattern suggests that the sepsis-cancer link is not a single blanket effect.
Immune Paralysis and Why It Matters for Tumors
Your immune system does not just fight infections. It also patrols for abnormal cells, including early-stage cancer cells that crop up naturally and usually get destroyed before they can form a tumor. One of the best-documented consequences of severe sepsis is a state sometimes called immunoparalysis, where the immune system, after an intense initial overreaction to infection, swings to the other extreme and becomes chronically underresponsive. This is not a brief dip. In some patients, immune function remains suppressed for months or even years after the sepsis episode resolves.
Animal experiments have shown that a key player in anti-tumor defense, a type of immune cell called a CD8 T cell, works far less effectively in sepsis survivors. In mice that had recovered from sepsis and were then exposed to tumor cells, the CD8 T cells that infiltrated the tumors produced roughly tenfold less of the signaling molecule they need to kill cancer cells compared to CD8 T cells in non-septic mice.3PubMed Central. Sepsis-induced state of immunoparalysis is defined by diminished CD8 T cell-mediated anti-tumor immunity Other research has shown that the broader T cell population in sepsis survivors tilts toward inhibitory signaling pathways that put the brakes on immune activity, further reducing the body’s ability to catch and eliminate rogue cells.4PubMed Central. Sepsis-induced long-term immune paralysis–results of a descriptive, explorative study
Meanwhile, the tumor microenvironment itself becomes more hospitable. In mouse models, sepsis survivors showed greater accumulation of a type of immune cell that, paradoxically, helps tumors grow rather than shrink. These pro-tumor immune cells were drawn to tumor sites in larger numbers in post-septic mice, and tumor progression was faster both in the weeks and months following sepsis.5PubMed. Post-Sepsis State Induces Tumor-Associated Macrophage Accumulation through CXCR4/CXCL12 and Favors Tumor Progression in Mice
DNA Damage and Epigenetic Reprogramming
Beyond weakening the immune patrol, sepsis inflicts direct molecular damage. Critically ill sepsis patients show significantly higher levels of DNA damage compared to healthy people. The primary driver is oxidative stress: the flood of reactive molecules released during the sepsis response physically breaks DNA strands. Researchers measuring this damage found that it correlated with markers of both oxidative stress and inflammation, establishing a direct link between the sepsis-driven inflammatory storm and genetic injury.6PubMed. Oxidative stress and DNA damage in critically ill patients with sepsis DNA damage does not automatically cause cancer, but it is one of the recognized starting points. Every time a cell divides with unrepaired damage, the odds of a cancer-promoting mutation go up.
Sepsis also leaves what amounts to a lasting molecular memory in stem cells and immune precursors. Hematopoietic stem cells, the bone marrow cells that give rise to all blood and immune cells, undergo epigenetic changes during sepsis. These changes alter which genes are switched on or off without rewriting the DNA sequence itself. Strikingly, these modifications persist long after the infection clears. When stem cells from a septic environment were transplanted into healthy mice, they still behaved abnormally, showing reduced ability to produce certain immune cell lineages and impaired long-term function.7Experimental Hematology. IMPACT OF SEPSIS ON EPIGENETIC REGULATION OF HEMATOPOIETIC STEM CELLS (HSC) Similar lasting epigenetic changes have been documented in bone marrow progenitor cells and the macrophages they produce, with transplant experiments confirming that the damage originates at the stem cell level and radiates outward.8PubMed Central. Sepsis Induces Prolonged Epigenetic Modifications in Bone Marrow and Peripheral Macrophages Impairing Inflammation and Wound Healing
This matters for cancer risk because epigenetic reprogramming can silence tumor-suppressor genes or activate growth-promoting pathways without a single mutation. It can also permanently weaken the immune cells that originate from those altered stem cells, compounding the immunoparalysis described above.
The Tissue Neighborhood Changes Too
Cancer does not grow in isolation. It depends on the surrounding tissue environment for nutrients, blood supply, and signals that either encourage or discourage growth. Sepsis reshapes that environment in ways that tend to favor tumors. One mechanism involves cellular senescence, a state where damaged cells stop dividing but do not die. Instead, they linger and pump out a cocktail of inflammatory molecules, growth factors, and enzymes that remodel the surrounding tissue. This secretory profile can promote tumor growth by altering neighboring cells, including stromal cells, immune cells, and any cancer cells that happen to be nearby.9PubMed Central. Cellular senescence and the tumour microenvironment
Sepsis generates plenty of senescent cells through the tissue damage it inflicts, and the resulting pro-inflammatory, pro-growth tissue environment can persist well beyond the acute illness. Combined with the blunted immune surveillance already discussed, the post-sepsis body offers something close to a welcome mat for nascent tumors.
The Shared Vulnerability Problem
An important caveat runs through all of this research: correlation is not causation, and some of the link between sepsis and cancer may reflect shared underlying risk factors rather than sepsis directly promoting malignancy. People who develop sepsis are often already immunocompromised, chronically ill, or older, and those same factors independently raise cancer risk. The U.S. Medicare study’s authors flagged this explicitly, noting that the elevated risk of myeloid leukemias after sepsis could partly reflect an underlying abnormal immune state that predisposes a person to both sepsis and leukemia. They pointed out that myeloid leukemia risk is also elevated in people with other immunosuppressive conditions, suggesting that something about the patient’s baseline immune function, not the sepsis episode itself, may be the deeper driver.10Clinical Infectious Diseases. Sepsis and Risk of Cancer Among Elderly Adults in the United States – Section: DISCUSSION
This does not mean the biological mechanisms discussed earlier are irrelevant. It means the real-world picture is a blend: sepsis probably worsens cancer risk through immune and molecular pathways, but it also tends to strike people who were already at higher baseline risk. Disentangling these contributions is one of the major unresolved challenges in the field.
Timing Matters in Unexpected Ways
One of the more striking findings from laboratory research is that the order of events, sepsis first or cancer first, dramatically changes the outcome. When mice are made septic and then exposed to tumor cells afterward, the tumors grow faster and more aggressively than in non-septic mice. But when the sequence is reversed, bacterial sepsis applied to mice that already have tumors, the opposite can happen: tumors sometimes shrink or even regress.11American Journal of Respiratory and Critical Care Medicine. Sepsis and Cancer: An Interplay of Friends and Foes
This paradox has deep historical roots. In the late 1800s, a New York surgeon named William Coley noticed that some cancer patients who developed severe post-surgical infections experienced tumor regression. He went on to deliberately inject bacteria into tumors, with mixed but occasionally dramatic results. What Coley stumbled onto, without the vocabulary to describe it, was essentially the acute inflammatory phase of what we now call sepsis being weaponized against existing tumors. The initial burst of immune activation can destroy cancer cells if a tumor is already present. It is only the later immunoparalysis phase, after the inflammatory storm has passed, that creates a permissive environment for new cancers to take hold. This timing dependence helps explain why the epidemiological data looks the way it does: it is the long-term survivors, months and years out from sepsis, who face higher cancer risk, not patients in the acute phase of illness.
ICU Treatments That May Compound the Risk
Sepsis patients spend days or weeks in intensive care, and some of the treatments they receive carry their own immune consequences. Blood transfusions, which are common in critically ill sepsis patients, can cause a phenomenon where the transfused blood products alter the recipient’s immune system. The effects range from immune suppression to inflammatory activation, and in surgical patients, this has been associated with cancer recurrence.12International Journal of Molecular Sciences. Molecular Mechanisms of Transfusion-Associated Immunomodulation and Its Impact in the Critically Ill In patients whose immune systems are already compromised from sepsis, this additional immune perturbation adds another layer of vulnerability.
Surgical stress itself can also play a role. In a mouse model, surgical stress alone increased the number of metastatic tumors in the lungs compared to controls. When polymicrobial sepsis was added on top of surgery, metastases climbed even higher, and the activity of natural killer cells, another key anti-tumor immune population, dropped significantly below the level seen with surgery alone.13bioRxiv. Sepsis Increases Perioperative Metastases in a Murine Model For patients who develop sepsis after a cancer surgery, this finding raises the concern that the infection may be actively undermining the surgical cure by allowing escaped cancer cells to seed new tumors.
The Bidirectional Relationship
The connection between sepsis and cancer runs in both directions. Cancer patients are substantially more likely to develop sepsis in the first place, owing to the immunosuppression caused by both the disease and its treatments (chemotherapy, radiation, prolonged hospitalizations with indwelling catheters). This creates a vicious feedback loop: cancer raises sepsis risk, and surviving sepsis may further weaken the immune system in ways that accelerate cancer progression or increase susceptibility to new malignancies.14PubMed Central. The Overlapping Biology of Sepsis and Cancer and Therapeutic Implications
Recognizing this bidirectional relationship has practical implications. Oncologists are increasingly aware that severe infections during cancer treatment do not just represent an acute threat to survival but may also alter the long-term trajectory of the cancer itself. And intensivists managing sepsis patients are beginning to think about cancer screening as part of long-term survivorship care, particularly for patients who were not previously known to have cancer.
What Sepsis Survivors Should Know
If you have survived a sepsis episode, the data does not mean cancer is inevitable. The absolute increases in cancer incidence are modest for most cancer types. But the evidence is strong enough that staying current on age-appropriate cancer screening is especially worthwhile. Many sepsis survivors already have regular follow-up with primary care physicians for other post-sepsis complications like cognitive changes, chronic fatigue, and recurrent infections, and cancer screening fits naturally into that ongoing care.
There is no specific post-sepsis anti-cancer intervention backed by clinical evidence yet. Researchers have explored whether immune-boosting therapies could reverse the immunoparalysis that contributes to cancer vulnerability, but these remain experimental. Some early work has looked at whether checkpoint inhibitor drugs, which are used in cancer immunotherapy, might help restore the exhausted T cells seen after sepsis, but this is still in the laboratory phase. For now, the practical advice is straightforward: keep up with screenings, report new symptoms promptly, and understand that the fatigue, immune difficulties, and general sense of vulnerability that many sepsis survivors describe are not just subjective, they reflect real biological changes that researchers are only beginning to map in full.